

Form PTO-1449 (modified)

Atty. Docket No.:

Serial No.:

10/521,140

**List of Patents and Publications for Applicant's****INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

**Applicant:**  
**Eva Kontsekova et al.****Filing Date:**  
October 31, 2005**Group:**  
1633**U.S. Patent Documents***See Page I***Foreign Patent Documents***See Page I***Other Art***See Pages 1-2***U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002-0010947	1/24/02	Gurney & Abraham	800	12	1/22/01
	A2	2006-0112437	5/25/06	Kontsekova et al.	435	6	11/1/05

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C39	Hammer et al., "Genetic engineering of mammalian embryos," <i>J. Anim. Sci.</i> , 63(1):269-278, 1986.
	C40	Hammer et al., "Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders," <i>Cell</i> , 63(5):1099-1112, 1990.
	C41	Hrnkova et al., "Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats," <i>Brain Res.</i> , 1130(1):206-213, 2007.
	C42	Ngo et al., "Computational complexity, protein structure prediction, and the levinthal paradox," in: Merz Jr. and LeGrand (Eds.), <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Birkhäuser, Basel, pages 491-495, 1994.
	C43	Office Action received in U.S. Application No. 10/521,049, mailed April 5, 2006.
	C44	Office Action received in U.S. Application No. 10/521,049, mailed July 10, 2006.
	C45	Office Action received in U.S. Application No. 10/521,049, mailed April 17, 2007.
	C46	Office Action received in U.S. Application No. 10/521,049, mailed November 28, 2007.
	C47	Office Action received in U.S. Application No. 10/521,049, mailed May 14, 2008.

55396244.1

EXAMINER: /Janet Epps Smith/

DATE CONSIDERED: 03/28/2009

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.E./

Form PTO-1449 (modified)		Atty. Docket No.: SONN:065US	Serial No.: 10/521,140
<b>List of Patents and Publications for Applicant's</b> INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			
		Filing Date: October 31, 2005	Group: 1633
<b>U.S. Patent Documents</b> <i>See Page 1</i>		<b>Foreign Patent Documents</b> <i>See Page 1</i>	<b>Other Art</b> <i>See Pages 1-2</i>

### **Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C48	Office Action received in U.S. Application No. 10/521,049, mailed November 13, 2008.
	C49	Shuman, "Production of transgenic birds," <i>Experientia</i> , 47:897-905, 1991.
	C50	Zilka <i>et al.</i> , "Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration <i>in vivo</i> ," <i>FEBS Lett.</i> , 580(15):3582-3588, 2006.

55396244.1

<b>EXAMINER:</b> /Janet Epps Smith/	<b>DATE CONSIDERED:</b> 03/28/2009
-------------------------------------	------------------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*  
**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.** /J.E./